background postprandial lipemia has been found to be strongly associated with atherosclerosis due to its atherogenic and thrombogenic lipoprotein changes. this phenomenon occurs even in normal subjects especially after high fat meals. orlistat, an anti- obesity drug, has been shown to address postprandial lipemia after a single high fat meal. objectives to compare the effects of orlistat and pl...

Background: Polycystic Ovary Syndrome (PCOS) is the commonest cause of anovulatory infertility. Treatment modes available are numerous. The use of anti-obesity medications such as orlistat or insulin sensitizing agents such as metformin is sometimes indicated in these patients. We aimed to compare the effect of metformin vs orlistat on the hormone, lipid profile &ovulation status in obese PCOS ...

BACKGROUND Postprandial lipemia has been found to be strongly associated with atherosclerosis due to its atherogenic and thrombogenic lipoprotein changes. This phenomenon occurs even in normal subjects especially after high fat meals. Orlistat, an anti- obesity drug, has been shown to address postprandial lipemia after a single high fat meal. OBJECTIVES To compare the effects of orlistat and ...

Fatty acid synthase (FASN), the sole protein capable of de novo synthesis of free fatty acids, is overexpressed in a wide variety of human cancers and is associated with poor prognosis and aggressiveness of these cancers. Orlistat, an FDA-approved drug for obesity treatment that inhibits pancreatic lipases in the GI tract, also inhibits the thioesterase (TE) of human FASN. The cocrystal structu...

OBJECTIVE The aim of this study was to determine and compare the effects of weight loss achieved through orlistat therapy alone or a combination of orlistat and an aerobic exercise training program on aerobic fitness and body composition in obese females. METHODS Twenty-eight obese patients were randomly assigned to receive 12-week treatment with hypocaloric diet-orlistat or diet-orlistat-exe...

Orlistat, an antiobesity drug, is cytostatic and cytotoxic to tumor cells. The antitumor activity of orlistat can be attributed to its ability to inhibit the thioesterase domain of fatty acid synthase (FAS). The objective of the present study was to test the effect of orlistat on endothelial cell proliferation and angiogenesis. Orlistat inhibits endothelial cell FAS, blocks the synthesis of fat...

Orlistat is a tetrahydrolipstatin, which inhibits both pancreatic and gastric lipase enzymes in the gut prevents absorption of dietary fats intestine. Therefore, it widely used as an anti-obesity medication to control manage body weight obese patients worldwide. Despite this, mounting number clinical studies report that orlistat treatment induces adverse effects like pancreatitis, hepatic failu...

Orlistat, an inhibitor of fatty acid synthase (FASN), acts as an antitumor agent by blocking de novo fatty acid synthesis of tumor cells. Although, myelopoiesis also depends on de novo fatty acid synthesis, the effect of orlistat on differentiation of macrophages, which play a central role in host's antitumor defence, remains unexplored in a tumor-bearing host. Therefore, the present investigat...

The inhibition of digestive lipases by the antiobesity drug Orlistat along with lipolysis levels and fecal fat excretion were measured in healthy humans. Orlistat was found to be a powerful gastric lipase inhibitor, achieving 46.6--91.4% enzyme inhibition and thus greatly reducing gastric lipolysis of solid and liquid meals (11--33% of respective controls). Gastric lipase inhibition by Orlistat...

OBJECTIVE To examine the risk of colorectal cancer after orlistat initiation in the UK population. DESIGN Retrospective matched cohort study. SETTING Data from the UK Clinical Practice Research Datalink from September 1998 to December 2008. PARTICIPANTS 33,625 adults aged 18 years or over who started treatment with orlistat; each orlistat initiator was matched to up to five non-initiators...